Skip to main content

Table 1 Demographic and clinical characteristics of RA patients treated with TCZ or TNFIs

From: Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry

Characteristics TCZ group (number = 302) TNFI group (number = 304) P value
Age, years 59.20 ± 13.04 57.33 ± 15.18 0.275
Female, % 82.5 82.8 0.425
Disease duration, years 10.20 ± 8.64 7.96 ± 8.70 <0.001
Steinbrocker’s stagea 51.0 35.2 <0.001
(III or IV), %
Steinbrocker’s classa 29.1 19.4 0.005
(3 or 4), %
Previous biologic use, % 70.5 10.5 <0.001
Number of previous non-biological DMARDs ≥3, % 47.0 38.5 0.034
DAS28CRP (3)b 4.50 ± 1.23 (n = 233) 4.25 ± 1.24 (n = 279) 0.019
Pulmonary diseasesc, % 20.2 15.5 0.128
Diabetes mellitus, % 10.9 10.5 0.873
Liver diseasesd, % 6.6 4.6 0.281
Kidney diseasese, % 3.6 0.7 0.011
MTX use, % 53.0 85.5 <0.001
MTX dose, mg/week 8.41 ± 2.80 8.54 ± 2.28 0.237
Oral corticosteroids use, % 65.6 51.0 <0.001
PSL-equivalent dosef, mg/day 5.32 ± 3.19 4.99 ± 3.05 0.433
  1. aSteinbrocker’s classification was used to define RA disease stages and classes; bDAS28CRP (3) was calculated based on three variables: swollen and tender 28-joint counts and CRP; cpulmonary diseases included interstitial lung disease, chronic obstructive pulmonary disease, and asthma; dliver diseases included hepatitis B carrier, hepatitis C carrier, fatty liver, hepatitis, primary biliary cirrhosis, positive anti-hepatitis C antibody, cholelithiasis, and abnormal liver function tests; ekidney diseases included nephrotic syndrome, nephritis, renal failure, chronic kidney disease, renal hypertension, hemi-kidney, and elevation of serum creatinine; fthe oral corticosteroids dose was converted to the equivalent prednisolone dosage. CRP; C-reactive protein; DAS28, disease activity score including 28-joint count; DMARDs, disease-modifying antirheumatic drugs; MTX, methotrexate; PSL, prednisolone; RA, rheumatoid arthritis; TCZ, tocilizumab; TNFIs, tumor necrosis factor inhibitors.